With all the brouhaha over the relative efficacy of prostate cancer screenings, you'd think the media would be watching for some really important news -- like a biomarker that could change the whole paradigm. Alas, the MSM seems to have missed the story entirely. Not shocking, but nevertheless disappointing considering the play they gave to the cost-effectiveness angle just last week.
But drugwonks won't let that happen
According to researchers from the
The
The study shows "that galectin-3 is cleaved during the progression of prostate cancer and might be associated with metastasis, cell growth and tumorigenicity. Expression of intact versus cleaved galectin-3 thus might be used as a marker for prognosis of prostate cancer and a therapeutic target for the treatment of prostate cancer," wrote study author Avraham Raz and colleagues.
Go Wolverines!
The study appears in the April issue of The American Journal of Pathology.